AHCYL1 (Adenosylhomocysteinase Like 1), also known as S-adenosylhomocysteine hydrolase-like 1 or SAHH-like, is a crucial enzyme in the methionine cycle that plays a fundamental role in cellular methylation reactions. This gene has garnered significant attention in neurodegenerative disease research due to its central position in one-carbon metabolism and its documented dysregulation in both Alzheimer's disease (AD) and Parkinson's disease (PD). [1]
The AHCYL1 protein is a member of the adenosylhomocysteinase family and shares structural and functional homology with the canonical S-adenosylhomocysteine hydrolase (AHCY), though it exhibits distinct tissue expression patterns and regulatory mechanisms. Its enzymatic activity directly influences the availability of S-adenosylmethionine (SAM), the universal methyl donor for DNA, RNA, protein, and lipid methylation reactions. [2]
| Property | Value |
|---|---|
| Gene Symbol | AHCYL1 |
| Full Name | Adenosylhomocysteinase Like 1 |
| Synonyms | SAHHL, SAHH2, DC4, C6orf68 |
| Chromosomal Location | 1p36.22 |
| NCBI Gene ID | 10768 |
| OMIM ID | 607551 |
| Ensembl ID | ENSG00000168710 |
| UniProt ID | O43865 |
| Protein Length | 442 amino acids |
| Molecular Weight | ~53 kDa |
AHCYL1 encodes a ~53 kDa enzyme that catalyzes the reversible hydrolysis of S-adenosylhomocysteine (SAH) to homocysteine and adenosine. This reaction is critically important because SAH is a potent inhibitor of methyltransferases when it accumulates. The enzymatic mechanism involves a two-step process:
The enzyme requires zinc for structural stability and catalytic activity, with the zinc-binding site located in the active site domain. [3]
AHCYL1 contains several important structural features:
AHCYL1 participates in several critical cellular processes:
AHCYL1 maintains cellular methylation capacity by preventing SAH accumulation. When AHCYL1 activity is compromised, SAH levels rise and inhibit methyltransferases, leading to global hypomethylation. This affects:
AHCYL1 plays a central role in homocysteine recycling. It converts SAH to homocysteine, which can then be recycled to methionine via the methionine synthase reaction or exported for cysteine synthesis. Proper homocysteine regulation is essential for:
The SAM:SAH ratio is a critical indicator of methylation capacity. AHCYL1 helps maintain this ratio by removing SAH, ensuring that methyltransferases can function optimally. A low SAM:SAH ratio is associated with:
AHCYL1 is involved in cellular stress responses, particularly:
AHCYL1 exhibits region-specific expression throughout the brain:
| Brain Region | Expression Level | Functional Significance |
|---|---|---|
| Hippocampus (CA1-CA3) | High | Critical for memory formation; vulnerable in AD |
| Cerebral Cortex (prefrontal) | High | Executive function; early AD involvement |
| Entorhinal Cortex | High | Gateway to hippocampus; early tau pathology |
| Substantia Nigra | Moderate | Dopaminergic neurons; PD vulnerability |
| Cerebellum | Moderate | Motor coordination; less affected in AD |
| Basal Ganglia | Moderate | Movement regulation |
| Brainstem | Low-Moderate | Autonomic functions |
AHCYL1 is expressed in multiple neural cell types:
Beyond the brain, AHCYL1 is expressed in:
Genome-wide association studies (GWAS) have identified AHCYL1 variants associated with increased AD risk. The 1p36.22 locus containing AHCYL1 shows suggestive association with late-onset AD. [1:1] Specific polymorphisms in the AHCYL1 promoter region may affect:
AHCYL1 dysfunction contributes to the methylation abnormalities observed in AD brain. Post-mortem studies of AD brain tissue reveal:
The methylation dysregulation affects several AD-relevant pathways:
Elevated homocysteine is a well-established risk factor for AD. AHCYL1 dysfunction contributes to homocysteine dysregulation through:
AHCYL1 may directly influence tau phosphorylation through methylation-dependent mechanisms. DNA hypomethylation can lead to increased expression of kinases that phosphorylate tau, including:
Targeting AHCYL1 and the methylation cycle offers therapeutic opportunities:
AHCYL1 is implicated in Parkinson's disease through several mechanisms [7]:
The methylation status of α-synuclein influences its aggregation propensity:
AHCYL1 deficiency may exacerbate mitochondrial dysfunction in PD:
AHCYL1 dysfunction contributes to cerebrovascular disease:
AHCYL1 may play a role in demyelination:
Methylation dysfunction is implicated in:
Systemic AHCYL1 dysfunction affects:
AHCYL1 sits at the intersection of multiple metabolic pathways:
AHCYL1-mediated methylation control affects:
AHCYL1 dysfunction contributes to neuroinflammation through [9]:
S-adenosylmethionine (SAMe) supplementation aims to:
Folate (B9), vitamin B12, and vitamin B6 supplementation:
Emerging therapeutic strategies include:
AHCYL1 and related metabolites show promise as biomarkers:
| Biomarker | Source | Clinical Utility |
|---|---|---|
| SAH | CSF, plasma | Disease progression marker |
| SAM:SAH ratio | CSF | Methylation capacity indicator |
| Homocysteine | Plasma | AD risk stratification |
| AHCYL1 autoantibodies | Serum | Potential autoimmune component |
Several trials have evaluated methylation-based interventions:
Several model systems have been used to study AHCYL1:
Several AHCYL1 variants have been characterized:
AHCYL1 variants may affect drug response:
Sweeney et al. AHCYL1 variants and Alzheimer's disease risk. Neurobiology of Aging. 2019. ↩︎ ↩︎
Dayem et al. S-adenosylhomocysteine metabolism in neuroinflammation. Journal of Neurochemistry. 2020. ↩︎
Barcelona-Sánchez et al. S-adenosylhomocysteine and cardiovascular disease in AD. Journal of Alzheimer's Disease. 2020. ↩︎
Chen et al. AHCYL1 methylation patterns in Alzheimer's disease brain. Alzheimer's & Dementia. 2021. ↩︎
Xu et al. AHCYL1 and tau pathology in Alzheimer's disease. Acta Neuropathologica Communications. 2019. ↩︎
Taylor et al. Cerebrovascular dysfunction and homocysteine in Alzheimer's disease. Stroke. 2020. ↩︎
Lee et al. One-carbon metabolism in Parkinson's disease. Movement Disorders. 2021. ↩︎
Park et al. AHCYL1 expression in substantia nigra of PD patients. Neurobiology of Disease. 2020. ↩︎
Zhang et al. AHCYL1 in microglial activation and neuroinflammation. Glia. 2022. ↩︎
Gómez et al. B-vitamin supplementation and homocysteine lowering in MCI. JAMA Neurology. 2020. ↩︎
Anderson et al. AHCYL1 genetic variants and therapeutic response. Pharmacogenomics Journal. 2021. ↩︎